Bioventus Inc
BVS · NASDAQ · Healthcare / Medical Devices
Price History
Full chartMarket Stats
About
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Company Details
- SectorHealthcare
- IndustryMedical Devices
- CEOMr. Robert E. Claypoole
- Employees950
- Headquarters4721 Emperor Boulevard, Durham, NC, United States, 27703, USA
- Websitehttps://www.bioventus.com
Leadership
- Mr. Robert E. ClaypoolePresident, CEO & Director · b. 1972
- Mr. Mark L. SingletonSenior VP & CFO · b. 1969
- Mr. Anthony D'Adamio J.D.Senior VP, General Counsel & Corporate Secretary · b. 1961
- Mr. Mike Crowe B.S., M.B.A.Senior Vice President of Operations
- Mr. David CrawfordVice President of Investor Relations & Treasurer
- Ms. Katrina J. Church J.D.Senior VP & Chief Compliance Officer · b. 1962
- Ms. Helen LeupoldSenior VP & Chief Human Resources Officer
- Mr. Dave VennerSenior VP & GM of Surgical
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Analyst Ratings
- Strong Buy2
- Hold1
Ownership Breakdown
- Institutions
- 83.08%
- Insiders
- 11.65%
- Retail / Other
- 5.27%
Top Institutional Holders
- Essex Woodlands Health Ventures13.02M19.06%
- Juniper Investment Co, LLC6.94M10.16%
- Nantahala Capital Management, LLC6.12M8.96%
- BlackRock Inc3.13M4.59%
- Vanguard Capital Management, LLC1.71M2.51%
- Royce & Associates, LP1.54M2.26%
- American Century Companies Inc1.35M1.98%
- Geode Capital Management, LLC1.17M1.71%
- Dimensional Fund Advisors, Inc.1.13M1.65%
- State Street Corp988.37K1.45%
- Vanguard Portfolio Management, LLC973.00K1.42%
- Hillsdale Investment Management Inc.907.74K1.33%
- Engine Capital Management LP900.56K1.32%
- Wellington Management Company LLP748.36K1.10%
Top Fund Holders
- Avantis US Small Cap Value ETF1.52M2.23%
- Brown Advisory Small-Cap Fdmtl Val Inv1.25M1.83%
- iShares Russell 2000 ETF1.23M1.81%
- Vanguard MStar Total Stk Mkt Idx Invest1.16M1.70%
- FTGF RY US SmCp Opp A USD Dis(A)927.00K1.36%
- Royce Small-Cap Opportunity Invmt858.74K1.26%